|
Costa Rica HPV Vaccine Trial (IR Travel)
|
Cures Moonshot18I2
|
$89,783
|
N/A
|
N/A
|
|
Costa Rica HPV Vaccine Trial (IR)
|
Cures Moonshot18I3
|
$1,078,107
|
N/A
|
N/A
|
|
IDDA - Partner - CDC
|
NIH-18-013
|
$678,899
|
N/A
|
N/A
|
|
IDDA - Partner - HRSA
|
NIH-18-017
|
$700,000
|
N/A
|
N/A
|
|
IDDA - Partner - CDC
|
NIH-18-018
|
$74,250
|
N/A
|
N/A
|
|
IDDA - Partner - CDC
|
NIH-18-025
|
$127,224
|
N/A
|
N/A
|
|
IGF::OT::IGF Hosting, Maintenance and Professional services for Rave and Medidata Rave Integrated Software
|
261201800033I
|
$5,576,825
|
-, -
|
-
|
|
The purpose of this procurement is to provide strategic planning and support service for the NCI CBITT
|
261201800285P
|
$24,876
|
-, -
|
-
|
|
Electronic Capture of Cancer Claims Data for SEER Program
|
261201800649P
|
$245,000
|
-, -
|
-
|
|
RIESSEARCH, LLC:1164941 [18-046091]
|
261201800744P
|
$22,800
|
-, -
|
-
|
|
IGF::OT::IGF CORE SUPPORT ACTIVITIES: SCIENTIFIC WRITING, TECHNICAL AND LOGISTICAL SUPPORT SERVICES
|
261201700004I
|
$1,200,000
|
BIZZELL, ANTON
|
-
|
|
BUSINESS ANALYST SERVICES TO ACHIEVE A BETTER UNDERSTANDING OF THE BUSINESS PROCESSES OF THE THE FEDERALLY FUNDED RESEARCH AND DEVELOPMENT CENTER (FFRDC) CONTRACTORS BUSINESS SYSTEMS.
|
261201800005A
|
$315,922
|
DURAND, HANK
|
-
|
|
CBCSLC CONTRACT FOR THE NCI CHEMICAL BIOLOGY CONSORTIUM, TO# 1
|
261201500010I
|
$275,323
|
JOHNSON, CHARLES
|
-
|
|
IGF::OT::IGF OPERATION & SUPPORT OF THE CTEP PROTOCOL AND INFORMATION OFFICE (PIO)
|
261201600003C
|
$1,232,875
|
KIERNAN, SHERYL
|
-
|
|
IGF::OT::IGF OTHER FUNCTIONS - IRB MANAGER SOFTWARE. OPTION YEAR TWO
|
261201600195P
|
$168,000
|
LEVERICH, WALDEN
|
-
|
|
IGF::OT::IGF CABEZON GROUP INC:1133841 [16-038312]
|
261201200005I
|
$50,125
|
RATEL, RACHEL
|
-
|
|
TOPIC 373 - PHASE I SBIR - ABZYME THERAPEUTICS, LLC - Moonshot
|
261201800031C
|
$299,999
|
N/A
|
ABZYME THERAPEUTICS, LLC
|
|
IGF::OT::IGF OTHER FUNCTIONS. Healthcare Delivery Research Visiting Scholars Program.
|
261201800642P
|
$51,283
|
-, -
|
ACADEMYHEALTH
|
|
Integrin Regulation of Cancer Progression Through Alternative mRNA Splicing and Nonsense-Medidated Decay (NMD)
|
5R01CA129637-08
|
$375,250
|
DIPERSIO, C MICHAEL
|
ALBANY MEDICAL COLLEGE
|
|
Novel Strategies for Precision T-cell Therapies
|
5R01CA198095-03
|
$520,564
|
ALMO, STEVEN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
A Major Nutritional Effect on Intestinal Stem Cells and Tumors
|
1R01CA214625-01A1
|
$294,022
|
AUGENLICHT, LEONARD
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Age and Diet: Major interacting factors that drive sporadic intestinal cancer
|
5R01CA174432-06
|
$660,173
|
AUGENLICHT, LEONARD
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
The sequence recognition, structure and function of the IMP family of mRNA binding proteins
|
5F30CA214009-02
|
$49,524
|
BISWAS, JEETAYU
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
MOTILITY AND INVASION
|
5P01CA100324-16
|
$2,028,990
|
CONDEELIS, JOHN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Signal transduction regulating tumor cell dissemination
|
5R01CA150344-30
|
$396,625
|
CONDEELIS, JOHN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
(7) Novel imaging devices for measurement and control of tumor microenvironments
|
5R01CA216248-02
|
$607,904
|
CONDEELIS, JOHN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
20/22 Diabetes Prevention Program Outcomes Study (DPPOS) Phase 3 - Research Project
|
5U01DK048349-26
|
$68,181
|
CRANDALL, JILL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Molecular analysis and therapeutic targeting of PI3K signaling in thyroid cancer
|
5R01CA128943-10
|
$396,625
|
DI CRISTOFANO, ANTONIO
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Designing Novel Anti-Cancer Therapeutics: Targeting Methionine Metabolism
|
5F30CA210372-02
|
$49,524
|
FIRESTONE, ROSS
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Small Molecule Activators of Pro-apoptotic BAX for Cancer Therapy
|
5R01CA178394-05
|
$346,525
|
GAVATHIOTIS, EVRIPIDIS
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Einstein-Rockefeller-CUNY Center for AIDS Research
|
5P30AI124414-02
|
$174,258
|
GOLDSTEIN, HARRIS
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
PI3K Isoform Dependence in Adult Hematopoiesis and Myeloid Leukemia
|
5R01CA196973-03
|
$415,736
|
GRITSMAN, KIRA
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
IGF::OT::IGF IGF::OF::IGF- PHASE III TRIAL OF CARBON ION THERAPY
|
261201500022C
|
$462,158
|
GUHA, CHANDAN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
B7x in Cancer: Mechanisms and Therapies
|
1F30CA224931-01
|
$49,524
|
JOHN, PETER
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Use of focused ultrasound to increase melanoma immunogenicity and inhibit tumor-induced T cell tolerance
|
1R01CA226861-01
|
$382,013
|
MACIAN, FERNANDO
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Microbial Metabolite Mimics, PXR and Colitis-Induced Colorectal Cancer
|
1R01CA222469-01
|
$549,306
|
MANI, SRIDHAR
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Paul Calabresi Career Development Award for Clinical Oncology (K12)
|
5K12CA132783-10
|
$508,802
|
PEREZ-SOLER, ROMAN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Investigating the role of Nol3 in normal and malignant hematopoiesis
|
1F30CA217063-01A1
|
$49,524
|
PISZCZATOWSKI, RICHARD
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Methylthioadenosine Phosphorylase and AdoMet Synthetase in Cancer
|
5R01CA135405-11
|
$290,592
|
SCHRAMM, VERN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Mechanisms of Formation and Progression of Preleukemic Stem Cells
|
5R01CA217092-02
|
$397,371
|
STEIDL, ULRICH
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
The B7x pathway in the tumor microenvironment
|
5R01CA175495-06
|
$346,525
|
ZANG, XINGXING
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Dissecting Skp2 functions in pRb and p53 doubly deficient tumorigenesis
|
5R01CA201458-03
|
$382,013
|
ZHU, LIANG
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
IGF::OT::IGF MANUFACTURE OF BULK CHEMICALS AND BULK PHARMACEUTICAL INGREDIENTS FOR PRECLINICAL AND CLINICAL STUDIES
|
261201700020C
|
$671,205
|
DENYSENKO, SERGIY
|
ALCHEM LABORATORIES CORPORATION
|
|
IGF::OT::IGF NON-GMP SYNTHESIS OF COMPOUNDS FOR DRUG DEVELOPMENT
|
261201600066C
|
$549,643
|
RUDCHENKO, VLADIMIR
|
ALCHEM LABORATORIES CORPORATION
|
|
IGF::OT::IGF SYNTHESIS OF 30 GRAMS OF THE TARGET COMPOUND, TASK ORDER PERIOD OF PERFORMANCE: 2/28/2018-4/27/2018.
|
261201700007I
|
$96,648
|
ZHANG, MIANJI
|
ALCHEM LABORATORIES CORPORATION
|
|
Molecular Biology in Clinical Oncology Workshop
|
5R25CA057732-26
|
$249,978
|
SAWYERS, CHARLES
|
AMERICAN ASSOCIATION FOR CANCER RESEARCH
|
|
Imaging and Radiation Oncology Core (IROC) Group
|
5U24CA180803-05
|
$8,285,739
|
FOLLOWILL, DAVID
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
IGF::OT::IGF SITE LICENSE TO AJCC CANCER STAGING MANUAL, 8TH EDITION, IN SUPPORT OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (DHHS), NATIONAL INSTITUTES OF HEALTH (NIH), NATIONAL CANCER INSTITUTE
|
261201800122P
|
$125,000
|
MADERA, MARTIN
|
AMERICAN COLLEGE OF SURGEONS
|
|
Young Investigator travel support for the 2016 through 2020 APS Annual Scientific Meetings
|
5R13AT009161-03
|
$5,000
|
PRICE, THEODORE
|
AMERICAN PAIN SOCIETY
|
|
Enhanced Training and Mentorship of Hematologic Oncologists
|
2R25CA168526-06
|
$306,150
|
SUNG, LILLIAN
|
AMERICAN SOCIETY OF HEMATOLOGY
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|